Contact information Verified work emails, personal emails, and direct dials — unlocked in one click.
Work email
•••••@biotissue.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••
Free to start · No credit card required
Current company BioTissue Ocular
Biotechnology Research · 375 employees · Founded 1997 · Miami, Florida, United States
BioTissue® is a pioneer & proven industry leader in eye care, harnessing the unique power of human birth tissue to support regenerative therapies for Ocular Surface Disease (OSD). Our portfolio of Cryopreserved Amniotic Membrane (CAM) products, including CAM360 AmnioGraft™, Prokera®, AmnioGraft®, and AmnioGuard®, use our proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural & functional integrity. CAM is the only Amniotic Membrane recognized by the FDA for anti-inflammation, anti-scarring, and anti- angiogenesis.1 Eye doctors use CAM360 AmnioGraft & Prokera biologic corneal bandage devices to treat ocular conditions including Neurotrophic Keratitis (NK), Persistent Epithelial Defects (PEDs), and many other Ocular Surface Diseases (OSDs). AmnioGraft can be used for surgical applications ranging from treating burns, primary & recurring pterygiums, and ocular surface reconstruction. AmnioGuard, derived from the umbilical cord, is commonly used by oculoplastic & glaucoma surgeons to provide tectonic support for treating corneal, scleral, socket, fornix, and eyelid cases. BioTissue is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since
its inception, clinicians have performed over 1 million human implants using CAM products and published 440 peer-reviewed publications supporting BioTissue’s platform technology.